ArticleJournal of clinical microbiology2012
Accurate and rapid identification of Candida spp. frequently associated with fungemia by using PCR and the microarray-based Prove-it Sepsis assay.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Nucleic Acid Amplification Tests forPathogens (Basel, Switzerland) · 2026Pooled it
- Omics and Multiomics-Based Diagnostics for Invasive Candidiasis: Toward Precision Medicine.Molecular & cellular proteomics : MCP · 2025Review
- Congenital Sepsis withMicroorganisms · 2024Review
- PCR-Based Microarray Enhances Diagnosis of Culture-Negative Biopsied Tissue in Patients with Invasive Mold Infections: Real-World Experience in a Tertiary Medical Center.Journal of fungi (Basel, Switzerland) · 2024Article
- The Evolving Landscape of Fungal Diagnostics, Current and Emerging Microbiological Approaches.Journal of fungi (Basel, Switzerland) · 2021Review
- Molecular Diagnosis of Yeast Infections.Current fungal infection reports · 2021Review
- Recent trends in molecular diagnostics of yeast infections: from PCR to NGS.FEMS microbiology reviews · 2019Review
- Rapid microbial identification and antimicrobial susceptibility testing to drive better patient care: an evolving scenario.The Journal of antimicrobial chemotherapy · 2019Article
- Non-culture based assays for the detection of fungal pathogens.Journal de mycologie medicale · 2018Review
- The identification and differentiation of the Candida parapsilosis complex species by polymerase chain reaction-restriction fragment length polymorphism of the internal transcribed spacer region of the rDNA.Memorias do Instituto Oswaldo Cruz · 2016Article
- The epidemiology and diagnosis of invasive candidiasis among premature infants.Clinics in perinatology · 2015Review
- Solid and Suspension Microarrays for Microbial Diagnostics.Methods in microbiology · 2015Article
- Identification and management of invasive mycoses in internal medicine: a road-map for physicians.Internal and emergency medicine · 2014Review
- Molecular diagnosis of sepsis: New aspects and recent developments.European journal of microbiology & immunology · 2014Article
- The potential for PCR based testing to improve diagnosis and treatment of sepsis.Current infectious disease reports · 2013Article
- Commercial multiplex technologies for the microbiological diagnosis of sepsis.Molecular diagnosis & therapy · 2013Review
- Candida infections and their prevention.ISRN preventive medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapid identification of microbes responsible for bloodstream infections (BSIs) allows more focused and effective therapies and outcomes. DNA sequence-based methods offer an opportunity for faster, accurate diagnosis and for effective therapy. As our objective of the study, the ability of the Prove-it Sepsis platform, already proven as a rapid PCR- and microarray-based assay for the majority of sepsis-causing bacteria, was extended to also rapidly identify clinically relevant yeasts in blood culture. The performance characteristics of this extended platform are described. We found that the extended diagnostic Prove-it Sepsis platform was found to be highly accurate when analyzing primary isolates, spiked blood cultures, nucleic acid extracts from a retrospective blood culture data set, and primary blood cultures. Comparison of the blood culture results from the Prove-it Sepsis platform with those from conventional culture-based methods or by gene sequencing demonstrated a sensitivity of 99% and a specificity of 98% for fungal targets (based on analysis of a total of 388 specimens). Total assay time was 3 h from DNA extraction to BSI diagnosis. These results extend the performance characteristics of the Prove-it platform for bacteria to the easy, rapid, and accurate detection and species identification of yeasts in positive blood cultures. Incorporation of this extended and rapid diagnostic platform into the tools for clinical patient management would allow possibly faster identification and more focused therapies for BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.